Logo image of SRRK

SCHOLAR ROCK HOLDING CORP (SRRK) Stock Overview

USA - NASDAQ:SRRK - US80706P1030 - Common Stock

32.34 USD
-1.33 (-3.95%)
Last: 9/16/2025, 8:00:00 PM
32.8 USD
+0.46 (+1.42%)
After Hours: 9/16/2025, 8:00:00 PM

SRRK Key Statistics, Chart & Performance

Key Statistics
52 Week High46.98
52 Week Low6.76
Market Cap3.11B
Shares96.13M
Float91.67M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.92
PEN/A
Fwd PEN/A
Earnings (Next)11-10 2025-11-10/bmo
IPO05-24 2018-05-24
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


SRRK short term performance overview.The bars show the price performance of SRRK in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 2 -2 -4

SRRK long term performance overview.The bars show the price performance of SRRK in the last 1, 2 and 3 years. 1 year 2 years 3 years 100 200 300

The current stock price of SRRK is 32.34 USD. In the past month the price increased by 2.6%. In the past year, price increased by 244.41%.

SCHOLAR ROCK HOLDING CORP / SRRK Daily stock chart

SRRK Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.42 382.04B
AMGN AMGEN INC 12.52 147.02B
GILD GILEAD SCIENCES INC 14.32 137.56B
VRTX VERTEX PHARMACEUTICALS INC 23.1 100.34B
REGN REGENERON PHARMACEUTICALS 12.6 60.95B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 60.46B
ARGX ARGENX SE - ADR 81.16 46.04B
ONC BEONE MEDICINES LTD-ADR 5.71 38.90B
INSM INSMED INC N/A 30.60B
NTRA NATERA INC N/A 24.02B
BNTX BIONTECH SE-ADR N/A 23.86B
BIIB BIOGEN INC 8.97 21.06B

About SRRK

Company Profile

SRRK logo image Scholar Rock Holding Corp. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 196 full-time employees. The company went IPO on 2018-05-24. The company is focused on advancing treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. Its products include SRK-439, SRK-181, SRK-373 and SRK-256. SRK-181 is a selective inhibitor of the activation of latent TGFb1, is being developed for the treatment of cancers.

Company Info

SCHOLAR ROCK HOLDING CORP

301 Binney Street, 3rd Floor

Cambridge MASSACHUSETTS 02142 US

CEO: Stuart A. Kingsley

Employees: 196

SRRK Company Website

SRRK Investor Relations

Phone: 18572593860

SCHOLAR ROCK HOLDING CORP / SRRK FAQ

What is the stock price of SCHOLAR ROCK HOLDING CORP today?

The current stock price of SRRK is 32.34 USD. The price decreased by -3.95% in the last trading session.


What is the ticker symbol for SCHOLAR ROCK HOLDING CORP stock?

The exchange symbol of SCHOLAR ROCK HOLDING CORP is SRRK and it is listed on the Nasdaq exchange.


On which exchange is SRRK stock listed?

SRRK stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for SCHOLAR ROCK HOLDING CORP stock?

16 analysts have analysed SRRK and the average price target is 51.58 USD. This implies a price increase of 59.5% is expected in the next year compared to the current price of 32.34. Check the SCHOLAR ROCK HOLDING CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is SCHOLAR ROCK HOLDING CORP worth?

SCHOLAR ROCK HOLDING CORP (SRRK) has a market capitalization of 3.11B USD. This makes SRRK a Mid Cap stock.


How many employees does SCHOLAR ROCK HOLDING CORP have?

SCHOLAR ROCK HOLDING CORP (SRRK) currently has 196 employees.


What are the support and resistance levels for SCHOLAR ROCK HOLDING CORP (SRRK) stock?

SCHOLAR ROCK HOLDING CORP (SRRK) has a support level at 31.41 and a resistance level at 35.07. Check the full technical report for a detailed analysis of SRRK support and resistance levels.


Should I buy SCHOLAR ROCK HOLDING CORP (SRRK) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does SCHOLAR ROCK HOLDING CORP (SRRK) stock pay dividends?

SRRK does not pay a dividend.


When does SCHOLAR ROCK HOLDING CORP (SRRK) report earnings?

SCHOLAR ROCK HOLDING CORP (SRRK) will report earnings on 2025-11-10, before the market open.


What is the Price/Earnings (PE) ratio of SCHOLAR ROCK HOLDING CORP (SRRK)?

SCHOLAR ROCK HOLDING CORP (SRRK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.92).


What is the Short Interest ratio of SCHOLAR ROCK HOLDING CORP (SRRK) stock?

The outstanding short interest for SCHOLAR ROCK HOLDING CORP (SRRK) is 18.36% of its float. Check the ownership tab for more information on the SRRK short interest.


SRRK Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to SRRK. When comparing the yearly performance of all stocks, SRRK is one of the better performing stocks in the market, outperforming 97.16% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

SRRK Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to SRRK. The financial health of SRRK is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SRRK Financial Highlights

Over the last trailing twelve months SRRK reported a non-GAAP Earnings per Share(EPS) of -2.92. The EPS decreased by -31.53% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -92.84%
ROE -135.32%
Debt/Equity 0.21
Chartmill High Growth Momentum
EPS Q2Q%-63.33%
Sales Q2Q%N/A
EPS 1Y (TTM)-31.53%
Revenue 1Y (TTM)N/A

SRRK Forecast & Estimates

16 analysts have analysed SRRK and the average price target is 51.58 USD. This implies a price increase of 59.5% is expected in the next year compared to the current price of 32.34.


Analysts
Analysts85
Price Target51.58 (59.49%)
EPS Next Y-33.22%
Revenue Next YearN/A

SRRK Ownership

Ownership
Inst Owners118.7%
Ins Owners3.74%
Short Float %18.36%
Short Ratio10.36